Jelle Wesseling

Citirano

	Sve	Od 2020.
Citati	23684	10339
H-indeks	80	48
i10-indeks	251	191

2200

1100

550

1650

199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202560 85 84 91 85 74 76 102 128 174 224 296 457 649 869 1012 1071 1342 1452 1539 1600 1542 1650 2033 2056 2033 2116 424

Javni pristup

Prikaži sve

122 članka

9 članaka

dostupno

nije dostupno

Na temelju uvjeta financiranja

Suautori

E Rutgershoogleraar chirurgische oncologie UvAPotvrđena adresa e-pošte na nki.nl
Sabine LinnProfessor of Translational Oncology - Utrecht University; Group leader NKI AmsterdamPotvrđena adresa e-pošte na nki.nl
Lodewyk WesselsProfessor of Computational Cancer BiologyPotvrđena adresa e-pošte na nki.nl
Kenneth GilhuijsAssociate professor, University Medical Center Utrecht, the NetherlandsPotvrđena adresa e-pošte na umcutrecht.nl
Marjanka K SchmidtNetherlands Cancer InstitutePotvrđena adresa e-pošte na nki.nl
Jos JonkersProfessor at Leiden University and group leader at Netherlands Cancer Institute, Oncode InstitutePotvrđena adresa e-pošte na nki.nl
Petra M NederlofNetherlands Cancer Institute NKIPotvrđena adresa e-pošte na nki.nl
Harm van TinterenHoofd Trial en Datacentrum, Prinses Maxima CentrumPotvrđena adresa e-pošte na prinsesmaximacentrum.nl
Valesca RetelPotvrđena adresa e-pošte na nki.nl
Erik van WerkhovenJohns Hopkins Bloomberg School of Public HealthPotvrđena adresa e-pošte na jhu.edu
J Bueno-de-MesquitaAntes / SprinkPotvrđena adresa e-pošte na sprink.nl
Elisabeth de VriesProfessor of Medical Oncology, University Medical Center Groningen, Groningen, the NetherlandsPotvrđena adresa e-pošte na umcg.nl
W. van HartenNetherlands Cancer Institute; Universiteit Twente, OECI, ex-CEO-Rijnstate, Innovation Fund Denmark.Potvrđena adresa e-pošte na hetnet.nl
Steven de JongProfessor of Preclinical and Translational Oncology, University Medical Center GroningenPotvrđena adresa e-pošte na umcg.nl
Hugo M. HorlingsMD PhD, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The NetherlandsPotvrđena adresa e-pošte na nki.nl
Truuske (G.H.) de BockHoogleraar Oncologische Epidemiologie UMCGPotvrđena adresa e-pošte na umcg.nl
Erik H. van BeersSanquin Diagnostic Services B.V.Potvrđena adresa e-pošte na sanquin.nl
Jakob de Vries MD PhDAssociate professor UMCGPotvrđena adresa e-pošte na umcg.nl
Jacques NeefjesHoogleraar cell biologie en immunologie, Leiden UniversiteitPotvrđena adresa e-pošte na nki.nl
Annuska M GlasQuantum Leap Healthcare Collaboration

Prati

Jelle Wesseling

Group Leader, Netherlands Cancer Institute

Potvrđena adresa e-pošte na nki.nl - Početna stranica

breast cancer pathology imaging treatment


Naslov Poredaj po navodima Poredaj po godini Poredaj po naslovu	Citirano Citirano	Godina
Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 … FM Blows, KE Driver, MK Schmidt, A Broeks, FE Van Leeuwen, ... PLoS medicine 7 (5), e1000279, 2010	1296	2010
Reversible and adaptive resistance to BRAF (V600E) inhibition in melanoma C Sun, L Wang, S Huang, GJJE Heynen, A Prahallad, C Robert, ... Nature 508 (7494), 118-122, 2014	936	2014
Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Wesseling, SW van der Valk, HL Vos, A Sonnenberg, J Hilkens The Journal of cell biology 129 (1), 255-265, 1995	545	1995
A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. J Wesseling, SW van der Valk, J Hilkens Molecular biology of the cell 7 (4), 565-577, 1996	482	1996
Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure M Donker, ME Straver, J Wesseling, CE Loo, M Schot, CA Drukker, ... Annals of surgery 261 (2), 378-382, 2015	477	2015
Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer RL Milne, KB Kuchenbaecker, K Michailidou, J Beesley, S Kar, ... Nature genetics 49 (12), 1767-1778, 2017	419	2017
Increased risk of fundic gland polyps during long‐term proton pump inhibitor therapy M Jalving, JJ Koornstra, J Wesseling, HM Boezen, S De Jong, ... Alimentary pharmacology & therapeutics 24 (9), 1341-1348, 2006	387	2006
Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk … LE Elshof, K Tryfonidis, L Slaets, AE van Leeuwen-Stok, VP Skinner, N Dif, ... European journal of cancer 51 (12), 1497-1510, 2015	380	2015
Personalized early detection and prevention of breast cancer: ENVISION consensus statement N Pashayan, AC Antoniou, U Ivanus, LJ Esserman, DF Easton, D French, ... Nature reviews Clinical oncology 17 (11), 687-705, 2020	371	2020
Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types S Jones, M Li, DW Parsons, X Zhang, J Wesseling, P Kristel, MK Schmidt, ... Human mutation 33 (1), 100-103, 2012	363	2012
Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised … MS van Ramshorst, A van der Voort, ED van Werkhoven, IA Mandjes, ... The Lancet Oncology 19 (12), 1630-1640, 2018	361	2018
Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER) JM Bueno-de-Mesquita, WH van Harten, VP Retel, LJ van't Veer, ... The lancet oncology 8 (12), 1079-1087, 2007	344	2007
Ductal carcinoma in situ: to treat or not to treat, that is the question M van Seijen, EH Lips, AM Thompson, S Nik-Zainal, A Futreal, ES Hwang, ... British journal of cancer 121 (4), 285-292, 2019	340	2019
The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer ME Straver, AM Glas, J Hannemann, J Wesseling, MJ van de Vijver, ... Breast cancer research and treatment 119, 551-558, 2010	340	2010
Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype CE Loo, ME Straver, S Rodenhuis, SH Muller, J Wesseling, ... Journal of Clinical Oncology 29 (6), 660-666, 2011	337	2011
Tissue distribution of the death ligand TRAIL and its receptors DC Spierings, EG de Vries, E Vellenga, FA van den Heuvel, JJ Koornstra, ... Journal of Histochemistry & Cytochemistry 52 (6), 821-831, 2004	332	2004
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients C Yau, M Osdoit, M van der Noordaa, S Shad, J Wei, D de Croze, ... The Lancet Oncology 23 (1), 149-160, 2022	324	2022
A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study CA Drukker, JM Bueno‐de‐Mesquita, VP Retèl, WH van Harten, ... International journal of cancer 133 (4), 929-936, 2013	300	2013
Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers EH Lips, L Mulder, A Oonk, LE Van Der Kolk, FBL Hogervorst, ALT Imholz, ... British journal of cancer 108 (10), 2172-2177, 2013	283	2013
Receptor conversion in distant breast cancer metastases LDC Hoefnagel, MJ van de Vijver, HJ Van Slooten, P Wesseling, ... Breast cancer research 12, 1-9, 2010	271	2010

Sustav trenutno ne može provesti ovu radnju. Pokušajte ponovo kasnije.

Članci 1–20

Godišnji broj citata

Dvostruki navodi

Spojeni navodi

Dodavanje suautoraSuautori

Prati

Citirano

Suautori